Godavari Drugs Limited (BOM:530317)
India · Delayed Price · Currency is INR 125.95
+0.95 (0.76%)
At close: Jun 17, 2026
Godavari Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,058 | 1,134 | 1,567 | 1,596 | 1,611 |
Other Revenue | 8.05 | 7.55 | 5.1 | - | 1.55 |
| 1,066 | 1,141 | 1,572 | 1,596 | 1,613 | |
Revenue Growth (YoY) | -6.57% | -27.42% | -1.50% | -1.01% | 31.31% |
Cost of Revenue | 774.98 | 828.66 | 1,222 | 1,295 | 1,328 |
Gross Profit | 291.16 | 312.39 | 350.35 | 301.26 | 284.42 |
Selling, General & Admin | 56.97 | 52.05 | 52.56 | 49.59 | 50.65 |
Other Operating Expenses | 122.99 | 131.45 | 158.07 | 133.08 | 116.86 |
Operating Expenses | 204.28 | 207.97 | 230.57 | 202.11 | 184.48 |
Operating Income | 86.88 | 104.42 | 119.78 | 99.15 | 99.94 |
Interest Expense | -39.8 | -47.32 | -49.15 | -39.27 | -28.49 |
Interest & Investment Income | - | 1.06 | 1.07 | 1.29 | 1.1 |
Currency Exchange Gain (Loss) | - | -3.07 | -1.58 | -18.03 | -2.34 |
Other Non Operating Income (Expenses) | - | 0.82 | - | 3.93 | - |
EBT Excluding Unusual Items | 47.08 | 55.91 | 70.12 | 47.05 | 70.21 |
Gain (Loss) on Sale of Assets | - | 0.35 | - | - | - |
Other Unusual Items | 3.55 | - | -0.9 | 2.3 | - |
Pretax Income | 50.63 | 56.25 | 69.22 | 49.35 | 70.21 |
Income Tax Expense | 9.74 | 12.45 | 13.73 | 11.49 | 17.75 |
Net Income | 40.89 | 43.8 | 55.49 | 37.86 | 52.45 |
Net Income to Common | 40.89 | 43.8 | 55.49 | 37.86 | 52.45 |
Net Income Growth | -6.64% | -21.07% | 46.57% | -27.82% | 27.06% |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 |
Shares Change (YoY) | 1.37% | -0.04% | 0.03% | 0.01% | -0.10% |
EPS (Basic) | 5.43 | 5.82 | 7.37 | 5.03 | 6.97 |
EPS (Diluted) | 5.36 | 5.82 | 7.37 | 5.03 | 6.97 |
EPS Growth | -7.90% | -21.03% | 46.52% | -27.83% | 27.19% |
Free Cash Flow | -259.9 | -88.02 | 52.12 | 38.81 | 59.85 |
Free Cash Flow Per Share | -34.07 | -11.70 | 6.92 | 5.16 | 7.95 |
Gross Margin | 27.31% | 27.38% | 22.28% | 18.87% | 17.64% |
Operating Margin | 8.15% | 9.15% | 7.62% | 6.21% | 6.20% |
Profit Margin | 3.84% | 3.84% | 3.53% | 2.37% | 3.25% |
Free Cash Flow Margin | -24.38% | -7.71% | 3.31% | 2.43% | 3.71% |
EBITDA | 111.2 | 128.9 | 144.26 | 118.58 | 116.9 |
EBITDA Margin | 10.43% | 11.30% | 9.18% | 7.43% | 7.25% |
D&A For EBITDA | 24.32 | 24.48 | 24.48 | 19.44 | 16.96 |
EBIT | 86.88 | 104.42 | 119.78 | 99.15 | 99.94 |
EBIT Margin | 8.15% | 9.15% | 7.62% | 6.21% | 6.20% |
Effective Tax Rate | 19.24% | 22.14% | 19.83% | 23.28% | 25.29% |
Revenue as Reported | 1,066 | 1,143 | 1,573 | 1,603 | 1,614 |